---
title: "兆科眼科-B：貝美前列素滴眼液 (晶貝清®) 獲國家藥監局批准上市"
description: "兆科眼科-B 宣佈，其研發的抗青光眼藥物貝美前列素滴眼液 (晶貝清®) 已獲得國家藥監局批准上市。這是中國首款不含防腐劑的單劑量貝美前列素滴眼液，旨在降低開角型青光眼及高眼壓症患者的眼壓，改善患者舒適感，並提高用藥依從性。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/214732882.md"
published_at: "2024-09-19T22:27:03.000Z"
---

# 兆科眼科-B：貝美前列素滴眼液 (晶貝清®) 獲國家藥監局批准上市

> 兆科眼科-B 宣佈，其研發的抗青光眼藥物貝美前列素滴眼液 (晶貝清®) 已獲得國家藥監局批准上市。這是中國首款不含防腐劑的單劑量貝美前列素滴眼液，旨在降低開角型青光眼及高眼壓症患者的眼壓，改善患者舒適感，並提高用藥依從性。

智通財經 APP 訊，兆科眼科-B(06622) 發佈公告，由公司研發生產的抗青光眼藥物貝美前列素滴眼液 (晶貝清®) 獲得國家藥品監督管理局 (國家藥監局) 批准上市。

貝美前列素滴眼液 (晶貝清®) 乃中國首款不含防腐劑的單劑量貝美前列素滴眼液，用於降低開角型青光眼及高眼壓症患者的眼壓。該款藥物不含防腐劑，避免青光眼患者因長期使用含有防腐劑的藥物而導致眼表受損。與此同時，該款藥物亦有助於改善患者於治療期間的舒適感，減少對防腐劑相關敏感的風險。其每日一次用藥頻率亦有助於提高患者依從性。

### Related Stocks

- [06622.HK - 兆科眼科-B](https://longbridge.com/zh-HK/quote/06622.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Saudi CMA Approves Public Offering Of Namaa Waqf Fund | SAUDI CMA :APPROVES PUBLIC OFFERING OF NAMAA WAQF FUND | [Link](https://longbridge.com/zh-HK/news/276066018.md) |
| Why has Kris Jenner's $13.5 million 'Keeping Up With the Kardashians' house sat on the market for over a year? | Kris Jenner's $13.5 million mansion, featured in "Keeping Up With the Kardashians," has been on the market for over a ye | [Link](https://longbridge.com/zh-HK/news/276110851.md) |
| Powerful storm in Redding bringing high wind, heavy rain, snow | A powerful winter storm is impacting Redding and Shasta County, bringing strong winds, heavy rain, and potential snow. W | [Link](https://longbridge.com/zh-HK/news/276082455.md) |
| French police raid Arab World Institute in Epstein-linked probe into Jack Lang | PARIS, Feb 16 (Reuters) - French police on Monday searched the Arab World Institute in Paris in connection with an inves | [Link](https://longbridge.com/zh-HK/news/276051725.md) |
| Greenland's west coast posts warmest January on record | Greenland's capital Nuuk recorded its warmest January ever, surpassing a 109-year-old record, with an average temperatur | [Link](https://longbridge.com/zh-HK/news/276050659.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。